Cervical Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Cervical Cancer, including details on symptoms, vaccine, screening, treatment, human papilloma virus (hpv), information.

Volume 4 (2007), Issue 2 (February)

1. Cervical cancer incidence in a prevaccine era in the United States, 1998-2002.
   Obstet Gynecol, 109(2): 360-70. [Abstract] [Full-text]
2. Preterm delivery after surgical treatment for cervical intraepithelial neoplasia.
   Obstet Gynecol, 109(2): 309-13. [Abstract] [Full-text]
3. Tumor carbonic anhydrase 9 expression is associated with the presence of lymph node metastases in uterine cervical cancer.
   Cancer Sci, 98(3): 329-33. [Abstract] [Full-text]
4. Human papillomavirus testing on self-sampled cervicovaginal brushes: an effective alternative to protect nonresponders in cervical screening programs.
   Int J Cancer, 120(7): 1505-10. [Abstract] [Full-text]
5. The major 8p22 tumor suppressor DLC1 is frequently silenced by methylation in both endemic and sporadic nasopharyngeal, esophageal, and cervical carcinomas, and inhibits tumor cell colony formation.
   Oncogene, 26(6): 934-44. [Abstract] [Full-text]
6. Human papillomavirus E7 repression in cervical carcinoma cells initiates a transcriptional cascade driven by the retinoblastoma family, resulting in senescence.
   J Virol, 81(5): 2102-16. [Abstract] [Full-text]
7. Gene dosage alterations revealed by cDNA microarray analysis in cervical cancer: identification of candidate amplified and overexpressed genes.
   Genes Chromosomes Cancer, 46(4): 373-84. [Abstract] [Full-text]
8. Suppression of the hypoxia-inducible factor-1 response in cervical carcinoma xenografts by proteasome inhibitors.
   Cancer Res, 67(4): 1735-43. [Abstract] [Full-text]
9. The human papillomavirus E6 oncogene dysregulates the cell cycle and contributes to cervical carcinogenesis through two independent activities.
   Cancer Res, 67(4): 1626-35. [Abstract] [Full-text]
10. ACTX-8, a cytotoxic L-amino acid oxidase isolated from Agkistrodon acutus snake venom, induces apoptosis in Hela cervical cancer cells.
    Life Sci, 80(13): 1189-97. [Abstract] [Full-text]
11. The relationship between cytokines and HPV-16, HPV-16 E6, E7, and high-risk HPV viral load in the uterine cervix.
    Gynecol Oncol, 104(3): 732-8. [Abstract] [Full-text]
12. Predictive value of HPV DNA in lymph nodes in surgically treated cervical carcinoma patients--a prospective study.
    Gynecol Oncol, 104(3): 721-6. [Abstract] [Full-text]
13. Age-specific detection of high risk HPV DNA in cytologically normal, computer-imaged ThinPrep Pap samples.
    Gynecol Oncol, 104(3): 702-6. [Abstract] [Full-text]
14. Correlation between survivin expression and locoregional control in cervical squamous cell carcinomas treated with radiation therapy.
    Gynecol Oncol, 104(3): 642-6. [Abstract] [Full-text]
15. The treatment of early stage cervical cancer: an assessment of pre-operative factors.
    Gynecol Oncol, 104(3): 665-9. [Abstract] [Full-text]
16. Prevention of adhesion formation after radical hysterectomy using a sodium hyaluronate-carboxymethylcellulose (HA-CMC) barrier: a cost-effectiveness analysis.
    Gynecol Oncol, 104(3): 739-46. [Abstract] [Full-text]
17. Hypermethylation of two consecutive tumor suppressor genes, BLU and RASSF1A, located at 3p21.3 in cervical neoplasias.
    Gynecol Oncol, 104(3): 629-35. [Abstract] [Full-text]
18. Increased expression of SKP2 and phospho-MAPK/ERK1/2 and decreased expression of p27 during tumor progression of cervical neoplasms.
    Gynecol Oncol, 104(3): 516-23. [Abstract] [Full-text]
19. Clinical impact of integrated PET/CT on the management of suspected cervical cancer recurrence.
    Gynecol Oncol, 104(3): 529-34. [Abstract] [Full-text]
20. Phase II clinical trial of capecitabine in the treatment of advanced, persistent or recurrent squamous cell carcinoma of the cervix with translational research: a gynecologic oncology group study.
    Gynecol Oncol, 104(3): 572-9. [Abstract] [Full-text]
21. Retinoic acid receptor beta2 is epigenetically silenced either by DNA methylation or repressive histone modifications at the promoter in cervical cancer cells.
    Cancer Lett, 247(2): 318-27. [Abstract] [Full-text]
22. Human papillomavirus testing and molecular markers of cervical dysplasia and carcinoma.
    Cancer, 111(1): 1-14. [Abstract] [Full-text]
23. Triage of women with ASCUS and LSIL cytology: use of qualitative assessment of p16INK4a positive cells to identify patients with high-grade cervical intraepithelial neoplasia.
    Cancer, 111(1): 58-66. [Abstract] [Full-text]
24. The Bethesda Interobserver Reproducibility Study (BIRST): a web-based assessment of the Bethesda 2001 System for classifying cervical cytology.
    Cancer, 111(1): 15-25. [Abstract] [Full-text]
25. Use of p63 for distinction of glandular versus squamous lesions in cervicovaginal specimens.
    Cancer, 111(1): 54-7. [Abstract] [Full-text]
26. HPV16 E6 variants and HLA class II polymorphism among Chinese women with cervical cancer.
    J Med Virol, 79(4): 439-46. [Abstract] [Full-text]
27. Distinctive distribution of HPV16 E6 D25E and E7 N29S intratypic Asian variants in Korean commercial sex workers.
    J Med Virol, 79(4): 426-30. [Abstract] [Full-text]

© 2004-2008 Cervical Cancer Research Today. All Rights Reserved.